Manus secures £2.6m to support the commercialisation of NeuroMotor PenTM
Summary
The Companys main activity is designing, patenting and marketing innovative technologies used in medical devices and personal care products which have the capability to improve peoples health and wellbeing. As a first indication, the pen has been configured for use in Parkinsons disease and tremor differentiation and uses limb and hand motion to diagnose patients quickly and non-invasively. There are additional applications in prevention screening, mBreakthrough Designation has been granted by the FDA for the proposed indication of using the NeuroMotor PenTM to support health care providers (HCPs) in differentiating between Parkinsonian and non-Parkinsonian tremors in adult patients who are suspected to have Parkinsons Disease (PD) but have not been diagnosed by other means.Par Equity is a leading, early-stage venture capital firm, investing in innovative, high growth technology companies. For more information about SIS Ventures, visit www.sisventures.comScottish Enterprise (SE) is Scotlands national economic development agency and a non-departmental public body of the Scottish Government. We have been supporting entrepreneurs since 2004, seeking out strong teams with great ideas that will drive high growth, scalable businesses, and sustainable charities.